Correspondence 0001193125-23-178529 from Enliven Therapeutics, Inc. (ELVN) (CIK 0001672619) (ELVN)
Enliven Therapeutics, Inc. (ELVN) (CIK 0001672619)
Date: June 29, 2023 · CIK: 0001672619 · Accession: 0001193125-23-178529
AI Filing Summary & Sentiment
File numbers found in text: 333-272909
Letter
Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder, Colorado 80301
June 29, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Enliven Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 23, 2023
File No. 333-272909
Acceleration Request
Requested Date:
July 3, 2023
Requested Time:
4:00 p.m. Eastern Time,
or as soon thereafter as practicable
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Enliven Therapeutics, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-272909) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Jennifer Knapp at (650) 849-3041.
Please direct any questions or comments regarding this acceleration request to Jennifer Knapp at (650) 849-3041.
[Signature Page Follows]
Very truly yours,
Enliven Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Enliven Therapeutics, Inc. 6200 Lookout Road Boulder, Colorado 80301 June 29, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Enliven Therapeutics, Inc. Registration Statement on Form S-3 Filed June 23, 2023 File No. 333-272909 Acceleration Request Requested Date: July 3, 2023 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Enliven Therapeutics, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-272909) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Jennifer Knapp at (650) 849-3041. Please direct any questions or comments regarding this acceleration request to Jennifer Knapp at (650) 849-3041. [Signature Page Follows] Very truly yours, Enliven Therapeutics, Inc. /s/ Samuel Kintz Samuel Kintz President and Chief Executive Officer cc: Tony Jeffries, Wilson Sonsini Goodrich & Rosati, Professional Corporation Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, Professional Corporation [Signature Page to the Company’s Acceleration Request]